Cited by 55Treatment of Major DepressionFunctional Brain Connectivity StudiesNeurotransmitter Receptor Influence on Behavior

The association between antidepressant treatment and brain connectivity in two double-blind, placebo-controlled clinical trials: a treatment mechanism study

Open access
Wang, Yun, Bernanke, Joel, Peterson, Bradley S, McGrath, Patrick, Stewart, Jonathan, Chen, Ying, Lee, Seonjoo, Wall, Melanie +5 more·2019·The Lancet Psychiatry

Abstract

Background Antidepressant medications offer an effective treatment for depression, yet nearly 50% of patients either do not respond or have side-effects rendering them unable to continue the course of treatment. Mechanistic studies might help advance the pharmacology of depression by identifying pathways through which treatments exert their effects. Toward this goal, we aimed to identify the effects of antidepressant treatment on neural connectivity, the relationship with symptom improvement, and to test whether these effects were reproducible across two studies.Methods We completed two double-blind, placebo-controlled trials of SNRI antidepressant medications with MRI scans obtained before and after treatment. One was a 10-week trial of duloxetine (30-120 mg daily; mean 92·1 mg/day [SD 30·00]) and the other was a 12-week trial of desvenlafaxine (50-100 mg daily; 93·6 mg/day [16·47]). Participants consisted of adults with persistent depressive disorder. Adjusting for sex and age, we examined the effect of treatment on whole-brain functional connectivity. We also examined correlations between change in functional connectivity and improvement in symptoms of depression (24-item Hamilton Depression Rating Scale) and pain symptom severity (Symptom Checklist-90-Revised).Findings Participants were enrolled between Jan 26, 2006, and Nov 22, 2011, for the duloxetine RCT and Aug 5, 2012, and Jan 28, 2016, for the desvenlafaxine RCT. Before and after treatment MRI scans were collected in 32 participants for the duloxetine RCT and 34 participants for the desvenlafaxine RCT. In both studies, antidepressants decreased functional connectivity compared with placebo (duloxetine study: β=-0·06; 95% CI -0·08 to -0·03; p<0·0001, η p2=0·44; desvenlafaxine study: -0·06, -0·09 to -0·03; p<0·0001, η p2=0·35) within a thalamo-cortico-periaqueductal network that has previously been associated with the experience of pain. Within the active drug groups, reductions in functional connectivity within this network correlated with improvements in depressive symptom severity in both studies (duloxetine study: r=0·38, 95% CI 0·01-0·65; p=0·0426; desvenlafaxine study: 0·44, 0·10-0·69; p=0·0138) and pain symptoms in the desvenlafaxine study (0·39, 0·04 to 0·65; p=0·0299).Interpretation The findings suggest the thalamo-cortico-periaqueductal network associated with the experience of pain is a new and potentially important target for novel antidepressant therapeutics.Funding National Mental Health Institute, Eli Lilly and Company, Pfizer Pharmaceuticals, and the Edwin S Webster Foundation.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s2215-0366(19)30179-8

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In a randomized controlled trial, MRI after treatment with duloxetine and desvenlafaxine showed that the thalamo-cortico-periaqueductal network, associated with the experience of pain, may be an important target of action of antidepressant drugs.

    “In a randomized controlled trial, MRI scan were taken after treatment with duloxetine and desvenlafaxine, and the results showed that the thalamo-cortico-periaqueductal network, which is associated with the experience of pain, may be an important target of action of antidepressant drugs. 374”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

1 of the 39 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Wang, Y., Bernanke, J., Peterson, B. S., McGrath, P., Stewart, J., Chen, Y., Lee, S., Wall, M., Bastidas, V., Hong, S., Rutherford, B. R., Hellerstein, D. J., & Posner, J.
Affiliations
  • New York State Psychiatric Institute (US)
  • Columbia University (US)
  • Children's Hospital Los Angeles (US)
Corresponding author
Posner, Jonathan
Venue
The Lancet Psychiatry
Publisher
Elsevier BV
Published
2019-08
Volume
6
Issue
8
Pages
667-674
ISSN
2215-0366 (ISSN-L)
OpenAlex
W2950299951
Cited by
55
References
39
Citations by year
2026: 3 · 2025: 7 · 2024: 8 · 2023: 5 · 2022: 13 · 2021: 10 · 2020: 7 · 2019: 2
FWCI
4.96
Type
journal article
Language
en
Open access
Locations
  • The Lancet Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
National Mental Health Institute grants (R01-MH101172, R01-MH036197)
Topics
  • Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
  • Life Sciences › Neuroscience › Cognitive Neuroscience › Functional Brain Connectivity Studies
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Keywords
antidepressant treatment, depression, functional connectivity, duloxetine, desvenlafaxine, serotonin-norepinephrine reuptake inhibitors, dysthymia, pain, therapeutic mechanisms, placebo response, symptom improvement, treatment response variability, treatment side effects
MeSH terms
Duloxetine Hydrochloride, Desvenlafaxine Succinate, Adult, Antidepressive Agents, Brain, Depressive Disorder, Double-Blind Method, Drug Administration Schedule, Female, Humans, Magnetic Resonance Imaging, Male, Middle Aged, Pain Measurement, Treatment Outcome, Connectome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review